Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 430

1.

Voice quality after treatment of early vocal cord cancer: a randomized trial comparing laser surgery with radiation therapy.

Aaltonen LM, Rautiainen N, Sellman J, Saarilahti K, Mäkitie A, Rihkanen H, Laranne J, Kleemola L, Wigren T, Sala E, Lindholm P, Grenman R, Joensuu H.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):255-60. doi: 10.1016/j.ijrobp.2014.06.032.

PMID:
25304787
[PubMed - in process]
2.

Early Pregnancy Sex Steroids and Maternal Breast Cancer: A nested case-control study.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso HA, Tanner MM, Kallio R, Joensuu H, Grankvist K, Zeleniuch-Jacquotte A, Toniolo P, Lundin E, Surcel HM.

Cancer Res. 2014 Oct 3. pii: canres.2150.2014. [Epub ahead of print]

PMID:
25281720
[PubMed - as supplied by publisher]
3.

Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma.

Morton LM, Gilbert ES, Stovall M, van Leeuwen FE, Dores GM, Lynch CF, Hall P, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Lamart S, Simon SL, Fraumeni JF Jr, Aleman BM, Curtis RE.

Haematologica. 2014 Oct;99(10):e193-6. doi: 10.3324/haematol.2014.108258. No abstract available.

PMID:
25271315
[PubMed - in process]
Free PMC Article
4.

Sunitinib-induced hypertension, neutropenia and thrombocytopenia as predictors of good prognosis in metastatic renal cell carcinoma patients.

Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.

BJU Int. 2014 Sep 23. doi: 10.1111/bju.12940. [Epub ahead of print]

PMID:
25252180
[PubMed - as supplied by publisher]
5.

Pancreatic cancer risk after treatment of Hodgkin lymphoma.

Dores GM, Curtis RE, van Leeuwen FE, Stovall M, Hall P, Lynch CF, Smith SA, Weathers RE, Storm HH, Hodgson DC, Kleinerman RA, Joensuu H, Johannesen TB, Andersson M, Holowaty EJ, Kaijser M, Pukkala E, Vaalavirta L, Fossa SD, Langmark F, Travis LB, Fraumeni JF Jr, Aleman BM, Morton LM, Gilbert ES.

Ann Oncol. 2014 Oct;25(10):2073-9. doi: 10.1093/annonc/mdu287. Epub 2014 Jul 25.

PMID:
25185241
[PubMed - in process]
6.

Dual targeting of HER2 with lapatinib and trastuzumab.

Joensuu H.

Lancet Oncol. 2014 Sep;15(10):1050-2. doi: 10.1016/S1470-2045(14)70342-0. Epub 2014 Aug 14. No abstract available.

PMID:
25130997
[PubMed - in process]
7.

ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer.

Kurppa KJ, Rokavec M, Sundvall M, Kellokumpu-Lehtinen PL, Joensuu H, Brauch H, Elenius K.

PLoS One. 2014 Jul 18;9(7):e102388. doi: 10.1371/journal.pone.0102388. eCollection 2014.

PMID:
25036186
[PubMed - in process]
Free PMC Article
8.

Trastuzumab emtansine: mechanisms of action and drug resistance.

Barok M, Joensuu H, Isola J.

Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621.

PMID:
24887180
[PubMed - in process]
Free PMC Article
9.

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.

Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P.

Cancer. 2014 Aug 1;120(15):2325-33. doi: 10.1002/cncr.28669. Epub 2014 Apr 15.

PMID:
24737415
[PubMed - in process]
Free Article
10.

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C.

Ann Oncol. 2014 Aug;25(8):1544-50. doi: 10.1093/annonc/mdu112. Epub 2014 Mar 7.

PMID:
24608200
[PubMed - in process]
11.

Prokineticins and Merkel cell polyomavirus infection in Merkel cell carcinoma.

Lauttia S, Sihto H, Kavola H, Koljonen V, Böhling T, Joensuu H.

Br J Cancer. 2014 Mar 18;110(6):1446-55. doi: 10.1038/bjc.2014.20. Epub 2014 Feb 4.

PMID:
24496457
[PubMed - indexed for MEDLINE]
12.

Novel target for peptide-based imaging and treatment of brain tumors.

Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, Närvänen A, Bergers G, Laakkonen P.

Mol Cancer Ther. 2014 Apr;13(4):996-1007. doi: 10.1158/1535-7163.MCT-13-0684. Epub 2014 Feb 3.

PMID:
24493698
[PubMed - in process]
13.

Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.

Arjonen A, Kaukonen R, Mattila E, Rouhi P, Högnäs G, Sihto H, Miller BW, Morton JP, Bucher E, Taimen P, Virtakoivu R, Cao Y, Sansom OJ, Joensuu H, Ivaska J.

J Clin Invest. 2014 Mar 3;124(3):1069-82.

PMID:
24487586
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Gastrointestinal stromal tumor: a method for optimizing the timing of CT scans in the follow-up of cancer patients.

Joensuu H, Reichardt P, Eriksson M, Sundby Hall K, Vehtari A.

Radiology. 2014 Apr;271(1):96-103. doi: 10.1148/radiol.13131040. Epub 2013 Nov 18.

PMID:
24475826
[PubMed - indexed for MEDLINE]
15.

Management of small gastrointestinal stromal tumours - Authors' reply.

Joensuu H, Hohenberger P.

Lancet. 2013 Nov 23;382(9906):1701-2. doi: 10.1016/S0140-6736(13)62398-3. No abstract available.

PMID:
24267995
[PubMed - indexed for MEDLINE]
16.

Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression.

Le Cesne A, Blay JY, Reichardt P, Joensuu H.

Oncologist. 2013;18(11):1192-9. doi: 10.1634/theoncologist.2012-0361. Epub 2013 Oct 17. Review.

PMID:
24136010
[PubMed - indexed for MEDLINE]
Free Article
17.

Gastrointestinal stromal tumors: risk assessment and adjuvant therapy.

Joensuu H.

Hematol Oncol Clin North Am. 2013 Oct;27(5):889-904. doi: 10.1016/j.hoc.2013.07.004. Epub 2013 Aug 2. Review.

PMID:
24093166
[PubMed - indexed for MEDLINE]
18.

Stomach cancer risk after treatment for hodgkin lymphoma.

Morton LM, Dores GM, Curtis RE, Lynch CF, Stovall M, Hall P, Gilbert ES, Hodgson DC, Storm HH, Johannesen TB, Smith SA, Weathers RE, Andersson M, Fossa SD, Hauptmann M, Holowaty EJ, Joensuu H, Kaijser M, Kleinerman RA, Langmark F, Pukkala E, Vaalavirta L, van den Belt-Dusebout AW, Fraumeni JF Jr, Travis LB, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2013 Sep 20;31(27):3369-77. doi: 10.1200/JCO.2013.50.6832. Epub 2013 Aug 26.

PMID:
23980092
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX).

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Saarni O, Helle L, Villman K, Nyandoto P, Nilsson G, Leinonen M, Kataja V, Bono P, Lindman H.

Acta Oncol. 2014 Feb;53(2):186-94. doi: 10.3109/0284186X.2013.820840. Epub 2013 Aug 19.

PMID:
23957715
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

New fronts in the adjuvant treatment of GIST.

Reichardt P, Joensuu H, Blay JY.

Cancer Chemother Pharmacol. 2013 Oct;72(4):715-23. doi: 10.1007/s00280-013-2248-0. Epub 2013 Aug 11. Review.

PMID:
23934322
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk